Genomic Vision announces TeloSizer® triathlon program to provide university researchers with a gateway to molecular telomere combing services
BAGNEUX, France – (COMMERCIAL THREAD) – Regulatory news:
Genomic vision (Paris: GV) (the “Company” – FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of genome modifications, today announces the availability of TeloSizer® Triathlon, a program offering academic researchers additional access to its new TeloSizer® services.
The TeloSizer® The triathlon program invites university researchers to submit projects in the areas of cancer, neurological disorders and age-related conditions. The projects will be selected by Genomic Vision, and three of them will receive free access to the company’s EasyComb Plus TeloSizer® services.
TeloSizer® The triathlon provides academics with access to powerful molecular combing technology for the quantification and physical measurement of telomeres. TeloSizer® Triathlon has the ability to help researchers studying cancer, neurological disorders and age-related conditions use molecular combing to determine the pathological mechanism (s) and therefore potentially speed up the identification of novel biomarkers based on telomeres.
“Since the launch of TeloSizer® we have seen strong interest from our target market. noted Dominique Rémy-Renou, CEO of Genomic Vision. “We created the TeloSizer® Triathlon program to support academic research in the telomere biology space to facilitate access to our TeloSizer® services with the aim of efficiently discovering new biomarkers based on telomeres.
Genomic Vision recently launched its brand new TeloSizer molecular combing service®, which enables detection, high-resolution imaging and quantification of the entire telomere genome. The new product offers greater accuracy compared to other telomere measurement methods including Flow-FISH, Q-FISH and real-time PCR.
TeloSizer® Triathlon offers telomere biomarker discovery projects in academia the opportunity to demonstrate molecular combing technology and observe the highest precision offered by TeloSizer® molecular combing.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as the quality and safety control of these modifications, in particular in genome editing technologies and processes. of bioproduction. Genomic Vision’s proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed for the high reliability characterization of DNA damage in the genome. These tools are mainly used for the monitoring of DNA replication in cancer cells, for the early detection of cancer and the diagnosis of genetic diseases. Genomic Vision, based in the Paris region in Bagneux, is a listed company listed on compartment C of the regulated market of Euronext in Paris (Euronext: GV – ISIN: FR0011799907).
For more information, please visit www.genomicvision.com
Member of the CAC® Medium and small and CAC® All-negotiable index
This press release implicitly or explicitly contains certain forward-looking statements regarding Genomic Vision and its business. These forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set out in the “Risk Factors” section of the universal registration document filed with the AMF on February 9. 2021 under the reference number R.21-002, available on the Genomic Vision website (www.genomicvision.com) and to changes in economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or currently considered not to be material by Genomic Vision. The occurrence of all or part of these risks could cause the actual results, financial conditions, performance or achievements of Genomic Vision to differ materially from these forward-looking statements.
This press release and the information it contains do not constitute and should not be interpreted as an offer or an invitation to sell or subscribe, or the solicitation of an order or an invitation to buy or subscribe for Genomic shares. Vision in any country. The distribution of this press release in certain countries may constitute a violation of applicable laws. Persons in possession of this press release should inform themselves of any local restrictions and comply with such restrictions.